PSD-95 in the anterior cingulate cortex contributes to neuropathic pain by interdependent activation with NR2B

Sci Rep. 2022 Oct 12;12(1):17114. doi: 10.1038/s41598-022-21488-7.

Abstract

Studies suggest that the scaffolding protein, postsynaptic density protein-95 (PSD-95), is involved in multiple neurological dysfunctions. However, the role of PSD-95 in the anterior cingulate cortex (ACC) in neuropathic pain (NP) has not been investigated. The current study addressed the role of PSD-95 in the ACC in NP and its modulating profile with NMDA receptor subunit 2B (NR2B). The NP model was established by chronic constriction injury (CCI) of the sciatic nerve, and mechanical and thermal tests were used to evaluate behavioral hyperalgesia. Protein expression and distribution were evaluated using immunohistochemistry and western blotting. The results showed that PSD-95 and NR2B were co-localized in neurons in the ACC. After CCI, both PSD-95 and NR2B were upregulated in the ACC. Inhibiting NR2B with Ro 25-6981 attenuated pain hypersensitivity and decreased the over-expression of PSD-95 induced by CCI. Furthermore, intra-ACC administration of PSD-95 antisense oligonucleotide not only attenuated pain hypersensitivity but also downregulated the NR2B level and the phosphorylation of cyclic AMP response element-binding protein. These results demonstrated that PSD-95 in the ACC contributes to NP by interdependent activation of NR2B.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Disks Large Homolog 4 Protein / metabolism
  • Gyrus Cinguli
  • Humans
  • Hyperalgesia
  • Neuralgia* / metabolism
  • Oligonucleotides, Antisense / metabolism
  • Receptors, N-Methyl-D-Aspartate / metabolism*

Substances

  • Cyclic AMP Response Element-Binding Protein
  • Disks Large Homolog 4 Protein
  • NR2B NMDA receptor
  • Oligonucleotides, Antisense
  • Receptors, N-Methyl-D-Aspartate